Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 427

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

The atopic march

Open access
Hill, David A., Spergel, Jonathan M.·2018·Annals of Allergy, Asthma & Immunology

Abstract

The atopic march refers to the natural history of allergic diseases as they develop over the course of infancy and childhood. Introduced by the American allergists A.F. Coca and R.A. Cooke in 1923, the term “atopy” became closely associated with the immunoglobulin (Ig) E molecule after its identification as the carrier of hypersensitivity.1 However, in the context of the atopic march, it is important to note that IgE is a pathophysiologic mediator of some, but not all, “atopic” diseases. As such, it is better to consider the atopic march as a progression of allergic conditions that have common genetic and environmental predisposing factors, share the immunologic feature of one or more allergen-specific T helper type 2 (TH2) responses, and are characterized by a “type 2” effector phase that can include generation of specific IgE, activation of granulocytes, and other innate features, such as mucous production and edema. Importantly, the presence of one allergic condition increases the risk for development of others, resulting in the additive feature of the atopic march. Classically, the atopic march begins with atopic dermatitis (AD), and progresses to IgE-mediated food allergy (FA), asthma, and allergic rhinitis (AR) (Figure 1).2 Each of these are conditions carry a complex pathophysiology involving multiple facets of the immune system. For example, AD was once considered a manifestation of atopy itself, but is now thought to result from a combination of primary skin defect(s) and underlying genetic or environmental propensity to develop type 2 inflammation. While non-type 2 inflammation likely contributes to AD pathophysiology, for the purposes of this review we will focus on the role of type 2 inflammation, as it is the central tenet of the atopic march. Due to the type 2 inflammation associated with AD lesions, AD also represents an important route of allergen exposure by which systemic TH2 responses are initiated. Once an individual has commenced on the atopic march, it is difficult to halt the progression. Here, we start with a clinical vignette and then review the epidemiologic and translational evidence supporting the concept of the atopic march. We briefly review the immunologic mechanisms that are thought to underlie the atopic march, and discuss some of the clinical interventions aimed at preventing or intervening upon the atopic march. Open in a separate window Figure 1 Age at diagnosis of common allergic conditions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.anai.2017.10.037

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 427

Metadata

Authors
Hill, D. A., & Spergel, J. M.
Venue
Annals of Allergy, Asthma & Immunology
Publisher
Elsevier BV
Published
2018-02
Volume
120
Issue
2
Pages
131-137
ISSN
1081-1206 (ISSN-L)
OpenAlex
W2786694607
Cited by
427
References
63
FWCI
20.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The atopic march. https://app.cochat.ai/papers/10.1016/j.anai.2017.10.037
The paper
Hill, D. A., & Spergel, J. M. (2018). The atopic march. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.anai.2017.10.037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.